Pattern and Visual Prognostic Factors of Behcet’s Uveitis in Northwest Iran

Abstract

Purpose: To investigate the pattern of ocular involvement in Behcet’s disease (BD) with predictors of patients’ final state of vision.


Methods: This historical cohort encompassed the clinical records of 200 patients diagnosed according to the International Criteria for BD (ICBD), over a period of 17 years between 2004 and 2021.


Results: The prevalence of Behcet’s uveitis (BU) was more common in females and patients in the fourth decade of life. Ninety-five patients (47.5%) had evidence of ocular involvement in the initial ophthalmologic evaluation, and 171 patients (85.5%) manifested evidence of BU during the follow-up visits of which bilateral non-granulomatous panuveitis was the most common anatomical pattern of involvement (32.9%) followed by posterior (27.6%), anterior (26.5%), and intermediate (13.8%) uveitis. The prevalent accompanying signs were oral aphthous (67%), skin lesions (29%), and genital ulcers (19.5%). Cystoid macular edema (CME) was the most frequent ocular complication (62%), followed by cataract (57.5%) and epiretinal membranes (ERM) (36.5%). Univariate analysis showed the following determinants: male gender, younger age at onset, panuveitis, posterior uveitis, retinal vasculitis, and longer duration of uveitis as poorer visual prognostic factors of the disease. Multivariate analysis demonstrated a higher chance of poor visual prognosis of BD in patients with panuveitis, posterior uveitis, retinal vasculitis, and longer duration of uveitis.


Conclusion: This cohort study demonstrated an overview on epidemiological patterns of BU along with the visual prognostic factors in Iranian patients.

Keywords:

Behcet’s Disease, Behcet’s Syndrome, Behcet’s Uveitis, Iran, Prognosis, Uveitis

References
1. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol 2018;14:107.

2. Çakar Özdal P. Behçet’s uveitis: current diagnostic and therapeutic approach. Turk J Ophthalmol 2020;50:169– 182.

3. Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH. Epidemiology of Behçet disease. Ocul Immunol Inflamm 2012;20:324–335.

4. Horie Y, Meguro A, Ohta T, Lee EB, Namba K, Mizuuchi K, et al. HLA-B51 carriers are susceptible to ocular symptoms of Behçet disease and the association between the two becomes stronger towards the east along the silk road: a literature survey. Ocul Immunol Inflamm 2017;25:37–40.

5. Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, et al. Genetics of Behçet disease inside and outside the MHC. Ann Rheum Dis 2010;69:747–754.

6. Tugal-Tutkun I, Onal S, Stanford M, Akman M, Twisk JWR, Boers M, et al. An algorithm for the diagnosis of Behçet disease uveitis in adults. Ocul Immunol Inflamm 2020;10:1–10.

7. Bagheri M, Ahoor MH, Jafari A, Hashemi HS, Mohammadkhani M. Pattern of uveitis in Iran: a systematic review. J Ophthalmic Vis Res 2021;16:93–102.

8. Ghavidel LA, Mousavi F, Bagheri M, Asghari S. Clinical course of uveitis in children in a tertiary ophthalmology center in northwest Iran. Crescent J Med Biol Sci 2017;4:200–204.

9. Davatchi F, Assaad-Khalil S, Calamia K, Crook J, Sadeghi- Abdollahi B, Schirmer M, et al. International team for the revision of the international criteria for Behçet’s disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28:338–347.

10. Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–516.

11. Taylor SR, Singh J, Menezo V, Wakefield D, McCluskey P, Lightman S. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011;152:1059–1066.

12. Al Akrash LS, Al Semari MA, Al Harithy R. Ocular manifestations of dermatological diseases part I: infectious and inflammatory disorders. Int J Dermatol 2021;60:5–11.

13. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2018: Behçet’s syndrome. Clin Exp Rheumatol 2018;36:13–27.

14. Amer R, Alsughayyar W, Almeida D. Pattern and causes of visual loss in Behçet’s uveitis: short-term and longterm outcomes. Graefes Arch Clin Exp Ophthalmol 2017;255:1423–1432.

15. Sáenz-Francés F, Elías-de-Tejada M, Martinez-De-La- Casa J, Calvo-González C, Fernández-Vidal A, Méndez- Hernández C, et al. Ocular inflammatory signs observed in a cohort of Spanish patients with Behçet disease and ocular inflammation. Eur J Ophthalmol 2008;18:563–566.

16. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297–350.

17. Accorinti M, Pesci FR, Pirraglia MP, Abicca I, Pivetti- Pezzi P. Ocular Behçet’s disease: changing patterns over time, complications and long-term visual prognosis. Ocul Immunol Inflamm 2017;25:29–36.

18. Sota J, Cantarini L, Vitale A, Sgheri A, Gentileschi S, Caggiano V, et al. Long-term outcomes of Behçet’s syndrome-related uveitis: a monocentric italian experience. Mediators Inflamm 2020;15:6872402.

19. Celiker H, Kazokoglu H, Direskeneli H. Factors affecting relapse and remission in Behçet’s uveitis treated with interferon Alpha2a. J Ocul Pharmacol Ther 2019;35:58– 65.